Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies

Clinical Cancer Research

Volumn 14, Issue 2, 2008, Pages 502-508

  Weiner, Louis M ^a   Belldegrun, Arie S ^b   Crawford, Jeffrey ^c   Tolcher, Anthony W ^d   Lockbaum, Pamela ^e   Arends, Rosalin H ^e   Navale, Lynn ^f   Amado, Rafael G ^f   Schwab, Gisela ^e   Figlin, Robert A ^b  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d University of Texas Health Science Center at San Antonio   (United States)

^e Abgenix Inc   (United States)

^f AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; IRINOTECAN; MAGNESIUM; OXALIPLATIN; PANITUMUMAB;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANGINA PECTORIS; ANOREXIA; ANUS CANCER; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COHORT ANALYSIS; COLORECTAL CANCER; CONSTIPATION; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG INFUSION REACTION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; DYSPNEA; ESOPHAGUS CANCER; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HYPOMAGNESEMIA; IMMUNOGENICITY; KIDNEY CANCER; LOADING DRUG DOSE; LUNG SMALL CELL CANCER; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; SKIN TOXICITY; SOLID TUMOR; STOMACH CANCER; STOMATITIS; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 38949178132     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1509     Document Type: Article

References (32)

1. Klapper LN, Kirschbaum MH, Sela M, et al. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 2000;77:25-79.
2. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37.
3. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990;61:203-12.
4. Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
5. Voldborg BR, Damstrup L, Spang-Thomsen M, et al. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol 1997;8:1197-206.
6. Sargent ER, Gomella LG, Belldegrun A, et al. Epidermal growth factor receptor gene expression in normal human kidney and renal cell carcinoma. J Urol 1989;142 :1364-8.
7. Yoshida K, Tosaka A. Epidermal growth factor binding by membranes of human renal cell carcinomas: establishment of an epidermal growth factor receptor assay for clinical use. Int J Urol 1994;1:319-23.
8. Yamanaka Y. The immunohistochemical expressions of epidermal growth factors, epidermal growth factor receptors and c-erbB-2 oncoprotein in human pancreatic cancer. Nippon Ika Daigaku Zasshi 1992;59:51-61.
9. Franklin WA, Veve R, Hirsch FR, et al. Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol 2002;29:3-14.
10. Porebska I, Harlozinska A, Bojarowski T. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERBB2, ERBB3) in colorectal adenocarcinomas and adenomas. Tumour Biol 2000;21:105-15.
11. Sridhar SS, Seymour L, Shepherd FA. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol 2003;4:397-406.
12. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005;23:2445-59.
13. Erbitux TM. Prescribing information. Branchburg (NJ): Imclone Systems, Inc.; 2006.
14. Yang XD, Jia XC, Corvalan JR, et al. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 1999;59:1236-43.
15. Hecht JR, Patnaik A, Berlin J, et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 2007;110:980-7.
16. Van Cutsem E, Peeters M, Siena S, et al. An open-label, randomized, phase3 clinical trial of panitumumab plus best supportive careversus best supportive care in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-64.
17. Hecht JR, Mitchell E, Baranda J, et al. Panitumumab activity in metastatic colorectal cancer (mCRC) patients (pts) with low or negative tumor epidermal growth factor receptor (EGFr) levels: an updated analysis. J Clin Oncol 2007;24:Abstract #3547.
18. Rowinsky EK, Schwartz GH, Gollob JA, et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 2004;22:3003-15.
19. WHO handbook for reporting results of cancer treatment. World Health Organization offset publication no. 48; Geneva (Switzerland):WHO; 1979.
20. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207-14.
21. Thomas M. Cetuximab: adverse event profile and recommendations for toxicity management. Clin J Oncol Nurs 2005;9:332-8.
22. Saltz LB, Meropol NJ, Loehrer PJ, Sr., et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-8.
23. Saltz LB, Kies M, Abbruzzese JL, et al. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol 2003;22:abstr 817.
24. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
25. Baselga J, Mendelsohn J. Receptor blockade with monoclonal antibodies as anti-cancer therapy. Pharmacol Ther 1994;64:127-54.
26. Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-5.
27. Boedigheimer M, Freeman D, Fitzpatrick D, et al. Gene expression profiles can predict panitumumab monotherapy responsiveness in xenograft models - a 'balanced' approach. Proc Am Assoc Cancer Res 2005;46:Abstract #1.
28. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005;6:279-86.
29. Hecht JR, Chidlac T, Mitchell E, et al. An interim analysis of efficacy and safety froma randomized controlled trial of panitumumab with chemotherapy plus bevacizumab (bev) for metastatic colorectal cancer (mCRC). Presented at the 9th World Congress of Gastrointestinal Cancer, June 27-30, 2007, Barcelona, Spain. Abstract no. O-0033.
30. Crawford J, Swanson P, Prager D, et al. Panitumumab, a fully human antibody, combined with paclitaxel and carboplatin versus paclitaxel and carboplatin alone for first line advanced non-small cell lung cancer (NSCLC): a primary analysis. Proc ECCO 2005:Abstract 1123.
31. Crawford J, Burris H, Stein M, et al. Safety and pharmacokinetics (PK) of AMG 706, panitumumab, and gemcitabine/cisplatin (GC) for the treatment of advanced solid malignancies. ASCO Annual Meeting Proceedings part I 2006. J Clin Oncol 2006;24(18S):abstract 13005.
32. Blumenschein G, Sandler A, O'Rourke T, et al. Safety and pharmacokinetics (PK) of AMG 706, panitumumab, and carboplatin/paclitaxel (CP) for the treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC). ASCO Annual Meeting Proceedings Part I 2006. J Clin Oncol 2006;24(18S):abstract 7119.